Three-year major clinical outcomes of phosphorylcholine polymer- vs biolinx polymer-zotarolimus-eluting stents: A propensity score matching study

Yong Hoon Kim, Ae Young Her, Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Jae Kyeong Byun, Yoonjee Park, Dong Oh Kang, Won Young Jang, Woohyeun Kim, Woong Gil Choi, Tae Soo Kang, Jihun Ahn, Sang Ho Park, Ji Young Park, Min Ho Lee, Cheol Ung Choi, Chang Gyu Park, Hong Seog Seo, Leonardo Roever

Research output: Contribution to journalArticle

Abstract

There are limited long-term outcome data comparing BioLinx polymer (B)-zotarolimus-eluting stents (ZES) with phosphorylcholine polymer (P)-ZES. The aim of this study was to compare the efficacy and safety of B-ZES with P-ZES in patients who underwent percutaneous coronary intervention (PCI) during a 3-year follow-up period.One thousand two hundred fifty four patients who underwent PCI with P-ZES (Endeavor [ZES-E] or Endeavor sprint [ZES-S], n=356) or B-ZES (Endeavor resolute [ZES-R] or Resolute Integrity [ZES-I], n=889) were enrolled. The primary endpoint was major adverse cardiac events (MACE); the composite of total death, non-fatal myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), non-target vessel revascularization (Non-TVR), and the secondary endpoint was stent thrombosis (ST).After PSM, 2 propensity-matched (PSM) groups (275 pairs, n=550, C-statistic=0.730) were generated. During the 3-year follow-up period, the cumulative incidence of MACE (hazard ratio [HR], 1.525; 95% confidence interval [CI], 0.920-2.526; P=.101) and ST (HR, 1.248; 95% CI, 0.335-4.4649; P=.741) were similar between P-ZES and B-ZES after PSM. However, TLR rate was significantly higher in ZES-S than ZES-I (11.3% vs 3.8%, log rank P=.029) and TVR rate was higher in ZES-S than ZES-R (14.1% vs 4.8%, log rank P=.025).In this single-center, all-comer registry, despite different polymers, P-ZES, and B-ZES showed comparable safety and efficacy during a 3-year follow-up period after PCI.

Original languageEnglish
Article numbere16767
JournalMedicine (United States)
Volume98
Issue number32
DOIs
Publication statusPublished - 2019 Aug 1

Keywords

  • BioLinx
  • clinical outcomes
  • drug-eluting stent
  • phoshorylcholine
  • Polymer
  • Zotarolimus

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Three-year major clinical outcomes of phosphorylcholine polymer- vs biolinx polymer-zotarolimus-eluting stents: A propensity score matching study'. Together they form a unique fingerprint.

  • Cite this

    Kim, Y. H., Her, A. Y., Rha, S-W., Choi, B. G., Choi, S. Y., Byun, J. K., Park, Y., Kang, D. O., Jang, W. Y., Kim, W., Choi, W. G., Kang, T. S., Ahn, J., Park, S. H., Park, J. Y., Lee, M. H., Choi, C. U., Park, C. G., Seo, H. S., & Roever, L. (2019). Three-year major clinical outcomes of phosphorylcholine polymer- vs biolinx polymer-zotarolimus-eluting stents: A propensity score matching study. Medicine (United States), 98(32), [e16767]. https://doi.org/10.1097/MD.0000000000016767